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Abstract 
Objective: Pulmonary cavitation is the classic hallmark of pulmonary tuberculosis (PTB) and is the site of very high 
mycobacterial burden associated with antimycobacterial drug resistance and treatment failure. The objective of this 
study was to investigate the relationship between re-treatment PTB and initial pulmonary cavitation coordinated with 
other clinical factors.
Methods: We conducted a case–control study of 291 newly diagnosed cases of pulmonary TB in The Infectious 
Hospital of Wuxi from Dec 2009 to Dec 2011 with complete follow-up information until December 31st of 2014. 68 
patients were followed-up with PTB re-treatment; the rest of the PTB patients (n = 223) had completed anti-TB treat-
ment, and cured without re-treatment were selected as controls.
Results: The univariate analysis [hazard ratio (HR) 1.885, 95 % CI 1.170–3.035, P = 0.009] and the multivariable analysis 
(HR 2.242, 95 % CI 1.294–3.882, P = 0.004) demonstrated that the initial pulmonary cavitation was a prognostic predic-
tor for TB re-treatment. Additionally, the re-treatment rates in PTB patients with cavitation and no-cavitation were 27.1 
and 15.5 %, respectively, with significant difference (log-rank test; P = 0.010). Other factors, age of ≥60 and history of 
smoking, were also prognostic variables.
Conclusion: Initial pulmonary cavitation of chest X-ray was a significant predictor for PTB re-treatment
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Background
According to Global tuberculosis report 2014, there 
were 5.7 million people had a new episode of tuberculo-
sis (TB) and 0.4 million had already been diagnosed with 
TB but treatment was changed to a re-treatment regi-
men [1]. China and India are having the greatest burden 
of disease. India and China accounted for 22 and 15  % 
of total cases, respectively, in 2014 [1]. The burden of 
tuberculosis (TB) in South Africa is the third highest in 
the world. In the most Western European countries and 
United States, the majority of cases occur in foreign-born 
residents and recent immigrants from countries in which 
tuberculosis is endemic [2–4].
TB is presenting new challenges as a major health prob-
lem. The most concerning situation is the re-treatment 
of patients who are often exposed to conditions associ-
ated with future failures that are attributable to micro-
bial resistance. The type of re-treatment TB included 
relapse, failure, treatment after default, or abandonment 
of treatment. The incidence of relapse TB in those who 
completed previous treatment can be 30 times higher 
than the incidence of TB in the general population [5]. 
Re-treatment of TB is associated with increased risk of 
drug resistance because of previous exposure to first-line 
anti-TB chemotherapy. In the recent global surveillance, 
it was estimated that 7.9 % of relapse cases were multid-
rug resistant TB for drug-resistant TB [6]. Re-treatment 
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encounter more side effects during treatment with sec-
ond-line drugs [7].
In this context, despite effective antimicrobial chemo-
therapy, re-treatment of tuberculosis (TB) after initial 
treatment remains a major challenge for TB control. 
Currently, more than 85 % initial patients were cured in 
China with an increase in coverage of directly observed 
treatment short-course (DOTS) therapy [8]. However, 
there still existed massive TB re-treatment patients in 
China due to the use of inadequate treatment regimens, 
the poor management of resistant cases, and the high 
transmission and mortality rates [8]. Moreover, with the 
large overall number of TB patients and the limited cure 
rate for re-treatment TB, the high overhead for re-treat-
ment cases should not be ignored in China.
Effective predictive factors for TB re-treatment help 
to identify those at high risk of re-treatment disease and 
reduce the disease burden through early intervention. 
The pulmonary cavitation is the classic hallmark of TB 
and is the site of very high mycobacterial burden. Pulmo-
nary cavitation is associated with antimycobacterial drug 
resistance [9] and treatment failure [10]. The presence of 
chest X-ray (CXR) cavitation is associated with a delayed 
therapeutic response. Patients with TB with pulmonary 
cavities are the principal source of disease transmission 
compared with those with non-cavitary disease [11–14]. 
However, there was still no direct evidence determining 
whether initial cavitation had the value to predict re-
treatment with pulmonary tuberculosis. In this study, we 
conducted a case–control study to explore the value of 
initial cavitation to predict tuberculosis re-treatment.
Methods
Study population and ethics statement
We conducted a case–control study from 371 newly 
diagnosed cases of pulmonary TB in The Infectious Hos-
pital of Wuxi from Dec 2009 to Dec 2011. A radiologist 
detected posterior–anterior CXRs of all newly diagnosed 
PTB patients for the presence or absence of cavities. A 
respiratory clinician reviewed all CXRs simultaneously. 
Then all of the newly diagnosed cases were admitted 
to our hospital to be hospitalized patients and received 
2 months of isoniazid (H), rifampicin (R), pyrazinamide 
(Z), and ethambutol (E) during an intensive phase and 
4  months of HR in the continuation phase. The dura-
tion of treatment was nearly 6  months. All information 
of patients was recorded in the clinical database of Infec-
tious Hospital of Wuxi. We extracted the following infor-
mation through medical chart review: age, sex, history 
of smoking, HIV status, cancer, DM, HBV/HCV status, 
coexisting extra-pulmonary TB, and bacteriologically 
confirmation. All patients were followed-up to Decem-
ber 31st of 2014. We excluded cases who transferred 
out (n  =  32), died during anti-TB treatment (n  =  20), 
and missed information (n = 28) with any other reasons 
during follow-up period. We adopted the WHO defini-
tion for TB treatment outcomes. After exclusion, finally, 
291 patients with complete follow-up information were 
included in this study. Meanwhile, 68 patients were fol-
lowed-up for TB re-treatment (Re-treatment was defined 
as patients who undergo second anti-TB treatment with 
active PTB after previous anti-TB treatment for one 
month or more). And, the rest of the no re-treatment 
PTB cases (n  =  223) had completed anti-TB treatment 
and cured without re-treatment was selected as controls 
(Fig. 1).
This study was approved by the Institutional Ethics 
Committee of Infectious Hospital of Wuxi, Affiliated to 
Jiangnan University (No: WXIH2009-022), and was in 
compliance with the national legislation and the Decla-
ration of Helsinki guidelines. Written patient consents 
were obtained according to the institutional guidelines.
Statistical methods
Statistical analysis was conducted using SPSS version 
17.0. Categorical variables were analyzed using Fisher 
exact tests and Chi-square tests, as appropriate, to iden-
tify significant differences across TB re-treatment cases 
and controls. Multivariable analysis was performed using 
Cox regression performed to determine the independent 
prognostic factors. Factors with a prognostic association 
in the univariate analysis were also entered into a multi-
variate Cox regression model. Results of the Cox regres-
sion modeling are presented as hazard ratios (HR) and 
associated 95 % confidence intervals (CI). The cumulative 
recurrence rate and curve during follow-up period was 
calculated using Kaplan–Meier analysis, and the log-rank 
test was utilized to examine the significance of the differ-
ences between different groups. P < 0.05 was considered 
as statistical difference for all analyses.
Results
Characteristics of the study participants
In the cohort study, we included all PTB patients from 
the study cohort during median follow-up period of 
3.25  years (IQR 3.0–4.1  years) (n  =  291). The median 
time from first treatment to second treatment of TB re-
treatment patients was 1.25  years (IQR 0.9–1.9  years) 
(n  =  68). Re-treatment was defined as patients who 
undergo second anti-TB treatment with active PTB after 
previous anti-TB treatment for one month or more. And, 
the rest of PTB cases who had completed anti-TB treat-
ment and cured without re-treatment was selected as 
controls (n = 223).
The distribution of sex did not differ between cases and 
controls (P = 0.707) (Table 1). Compared to controls, cases 
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were more likely to be patients with age ≥60 (P < 0.001), 
more likely to be smokers (P = 0.020), and more likely to 
present with initial cavitation (P < 0.001). The prevalence 
of DM, cancer, HBV/HCV, and extra-pulmonary lesion 
were higher among cases than controls (13.2 vs. 9.8  %, 
8.8 vs. 3.6 %, 17.6 vs. 10.8 %, 23.5 vs. 18.8 %, respectively) 
without significance. Thirty-two (50.0  %) re-treatment 
cases had bacteriological evidence for active TB disease, 
and ninety-one (43.5 %) controls with bacteriological con-
firmation due to there were 2 cases and 14 controls miss-
ing information in bacteriologically test.
Result of univariate analysis demonstrated that initial 
cavitation was a prognostic predictor for TB re-treatment 
[hazard ratio (HR) 1.885, 95 % CI 1.170–3.035, P = 0.009]. 
Other prognostic variables presented in Table  2 were 
age of ≥60 (HR 2.280, 95  % CI 1.371–3.790, P =  0.001) 
and history of smoking (HR 1.771, 95 % CI 1.086–2.888, 
P = 0.022). In the multivariable analysis, we included only 
66 cases and 209 controls because of missing information 
in bacteriologically test. Initial cavitation of chest X-ray 
was also a prognostic predictor associated with re-treat-
ment of TB (HR 2.242, 95 % CI 1.294–3.882, P = 0.004). 
Other prognostic factors, age of ≥60 (HR 2.044, 95 % CI 
1.201–3.478, P  =  0.008), history of smoking (HR 1.835, 
95 % CI 1.012–3.321, P = 0.045), cancer (HR 2.831, 95 % 
CI 1.178–6.805, P = 0.020), HBV/HCV (HR 2.636, 95 % 
CI 1.343–5.172, P =  0.005), and coexisting of extra-pul-
monary (HR 1.984, 95 % CI 1.094–3.598, P = 0.024) were 
also associated with TB re-treatment. However, gender, 
bacteriologically confirmation, and patients with DM 
were not confirmed to be prognostic factors with TB re-
treatment in this study.
The re-treatment rate increased with the follow-up 
time. The re-treatment rates in APTB patients with ini-
tial cavitation and no-cavitation are shown in Fig.  2; 
they were 32.3 and 18.8  %, respectively, with significant 
Fig. 1 Flow diagram for the enrollment of study participants in the nested case–control study
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difference (log-rank test, P  =  0.008). The different re-
treatment rates in APTB patients with age of ≥60, his-
tory of smoking, and cancer compared to age of  <60, 
no-smoking, and no-cancer were also significant (18.4 vs 
15.3 %, log-rank test, P = 0.001; 29.2 vs 17.3 %, log-rank 
test, P =  0.02; 42.9 vs 32.4  %, log-rank test, P =  0.048, 
respectively). However, the different re-treatment rates in 
APTB patients with HBV/HCV and EB were without sig-
nificant difference (log-rank test, P = 0.187 and log-rank 
test, P = 0.327, respectively).
Discussion
Tuberculosis (TB) re-treatment still remains a major 
health problem despite an increase in coverage of directly 
observed treatment short-course (DOTS) therapy and 
adoption of passive case detection in China [8] due to 
perpetuate TB transmission and high rates of recurrent 
disease. Moreover, re-treatment of TB is associated with 
increased risk of drug resistance because of previous expo-
sure to first-line anti-TB chemotherapy. Better under-
standing of the factors of TB re-treatment helps identify 
those at high risk of re-treatment disease and promises to 
reduce the disease burden through risk factor intervention.
Some investigators showed an association between 
anti-tuberculosis drug resistance [9] and treatment fail-
ure [10] with pulmonary cavitation; patients with TB with 
pulmonary cavities was the principal source of disease 
transmission compared with those with non-cavitary dis-
ease [11–14], and the presence of CXR cavitation is also 
linked with a delayed therapeutic response. In this study, 
we conducted a cohort study to explore the relationship 
between initial cavitation with tuberculosis re-treatment. 
The evidence indicated strongly that initial cavitation was 
a risk factor for PTB re-treatment and had the significant 
value to predict patients’ re-treatment with pulmonary 
tuberculosis. Moreover, the re-treatment rates in APTB 
patients with initial cavitation were higher than patients 
without cavitation during the follow-up time. It is the 
first report about the relationship between chest cavita-
tion and PTB re-treatment as known.
Pulmonary cavitation is the classic hallmark of TB and 
is the site of very high mycobacterium tuberculosis (M.tb) 
burden. The high M.tb burden maybe one of causes for 
PTB re-treatment. M.tb infection triggers recruitment and 
infection of leukocytes and the activation of intercellular 
networks, which then result in damage, with tissue destruc-
tion [15]. Successful immune responses result in granulo-
mas and curtailment of disease, while cavitation indicates 
a failing immune response [16]. Cavitation was associ-
ated with local neutrophilia and relative lymphopenia, 
whereas lymphocytosis and lower levels of granulocytes 
were detected from areas of pulmonary infiltrates and also 
from radiologically unaffected lobes [17]. The lymphopenia 
Table 1 Characteristics of the study participants





Cavitation on initial 
CXR
32 (47.1) 67 (30.0) <0.001
Age (year)
 <60 22 (32.4) 101 (45.3) <0.001
 ≥60 46 (67.6) 122 (54.7)
 Sex, male 50 (73.5) 169 (75.8) 0.707
History of smoking 42 (61.2) 102 (45.7) 0.020
Cancer 6 (8.8) 8 (3.6) 0.098
DM 9 (13.2) 22 (9.8) 0.441
HBV/HCV 12 (17.6) 24 (10.8) 0.145
Coexisting of extra-
pulmonary lesion




32 (50.0) 91 (43.5) 0.364
Table 2 Univariable and  multivariable odds ratios for  the associations between  potential risk factors and TB re-treat-
ment
Unadjusted hazard ratio (95 % CI) P Adjusted hazard ratio (95 % CI) P
Initial cavitation 1.885 (1.170–3.035) 0.009 2.242 (1.294–3.882) 0.004
Age (year)
 <60 Reference Reference
 ≥60 2.280 (1.371–3.790) 0.001 2.044 (1.201–3.478) 0.008
 Sex, male 0.914 (0.533–1.567) 0.744 0.593 (0.311–1.130) 0.112
History of smoking 1.771 (1.086–2.888) 0.022 1.835 (1.012–3.321) 0.045
Cancer 2.269 (0.981–5.246) 0.055 2.831 (1.178–6.805) 0.020
DM 1.323 (0.656–2668) 0.434 1.864 (0.882–3.936) 0.103
HBV/HCV 1.514 (0.812–2.825) 0.192 2.636 (1.343–5.172) 0.005
Coexisting of extra-pulmonary 1.320 (0.754–2.313) 0.331 1.984 (1.094–3.598) 0.024
Culture positive or/and smear-positive 1.188 (0.733–1.926) 0.484 0.854 (0.494–1.477) 0.573
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affected patients’ immune ability to prevent M.tb reactiva-
tion which could be inclined to disease re-treatment.
Other prognostic variables included age of  ≥60 and 
history of smoking were also prognostic predictors asso-
ciated with re-treatment of TB. Other independent risk 
factors for re-treatment included the presence of HBV/
HCV and extra-pulmonary were associated with TB re-
treatment in the multivariable analysis but not in the 
univariable analysis. However, gender, DM, cancer, and 
bacteriologically confirmation were not confirmed to be 
factors with TB re-treatment.
Our study also had limitations. The eligible patients 
represented a fraction of the patients diagnosed with 
active tuberculosis during the study period, raising a 
concern for a selection bias. Other risk factors for re-
treatment in mainly new patients were described in other 
settings, such as health knowledge, distance to treatment 
center, and patients’ economic status; these could not 
however be assessed in this study [18, 19].
Except for these limitations above, the initial pulmo-
nary cavitation in PTB patients was predictive for TB 
re-treatment. Additionally, the re-treatment rates in PTB 
patients with initial cavitation were higher than patients 
without cavitation. Other factors, especially patients with 
history of smoking, and age of ≥60 also had higher risk 
for re-treatment. Due to the large amount of TB patients 
and the limited cure rate for PTB re-treatment in China, 
the high overhead for PTB re-treatment cases should not 
be ignored. We recommend that chest X-ray monitoring 
are needed to confirm initial cavitation of PTB patients 
to control the risk of PTB re-treatment, an issue requir-
ing early attention to avoid TB re-treatment.
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Fig. 2 Cumulative re-treatment with months after primary treatment. a Cumulative re-treatment during follow-up period in APTB patients with 
cavitation and no-cavitation (Kaplan–Meier); b–d the different re-treatment rates in APTB patients with age of ≥60, history of smoking, and cancer 
compared to age of <60, no-smoking, and no-cancer (Kaplan–Meier); e, f Cumulative re-treatment during follow-up period in APTB patients with 
HBV/HCV and EB (extra-pulmonary) compared to no-HBV/HCV and no-EB (Kaplan–Meier)
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